Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Itopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.96 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 2/20 | 0.96 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.75 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 2/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itopride SCHEMBL311309 | 0.98 | DRD2 (1.00) | DRD2DRD3HRH3LMNAACHE | |
| Itopride SCHEMBL554675 | 0.97 | DRD2 (0.98) | DRD2DRD3HRH3LMNAACHE | |
| SCHEMBL9815695 | 0.92 | DRD2 (0.88) | DRD2DRD3HRH3LMNAACHE | |
| SCHEMBL23731302 | 0.89 | DRD2 (0.84) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL3059009 | 0.89 | DRD2 (0.96) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL6683399 | 0.87 | DRD2 (1.00) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL28858 | 0.87 | DRD2 (1.00) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL41339 | 0.86 | SMN1; SMN2 (1.00) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL4586062 | 0.86 | DRD2 (0.98) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL4586216 | 0.86 | SMN1; SMN2 (1.00) | DRD2DRD3HRH3LMNAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250259704-A1 | SYSTEMS AND METHODS FOR CELL-FREE ITERATIVE SITE SATURATION MUTAGENESIS AND ITS APPLICATION FOR THE DIRECTED EVOLUTION OF ENZYMES CATALYZING UNNATURAL REACTIONS | U.S. DEPARTMENT OF ENERGY | 2025-08-14 | — | — | US | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| CN-113009003-B | Method for detecting related substances in itopride hydrochloride preparation | 珠海润都制药股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111693633-B | Method for detecting 3,4-dimethoxy benzoyl chloride in itopride hydrochloride | 珠海润都制药股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-113735740-A | Preparation method of demethyl itopride nitrosamine | 珠海润都制药股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-113720947-A | Detection method of demethylitopride nitrosamine | 珠海润都制药股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113009003-A | Method for detecting related substances in itopride hydrochloride preparation | 珠海润都制药股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-111693633-A | Method for detecting 3,4-dimethoxy benzoyl chloride in itopride hydrochloride | 珠海润都制药股份有限公司 | 2020-09-22 | — | — | CN | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | DRD2 2444/4885ACHE 1845/4885DRD3 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.